Compare Linde PLC (LIN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Tango Therapeutics Inc. — how do they compare? Linde PLC trades at $495.32 (market cap $226.85B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Linde PLC is far larger — about 60.5× Tango Therapeutics Inc.'s market cap, and Linde PLC pays a 1.3% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 89 Days and Tango Therapeutics Inc. for 0 Days on average.
| LIN | TNGX | |
|---|---|---|
Market Cap | $226.85B | $3.75B |
Volume | 1,386,042 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $32.90 |
52-Week Low | $389.38 | $7.50 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $249.97B | $2.77B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $492.11, up 0.98% today, near its 52-week high. The stock shows a bullish technical trend with strong fundamentals, including a 20.43% net income margin and consistent earnings beats. Recent news highlights its role in AI chip supply chains, while analyst consensus remains strongly positive with a $558.91 price target.
Outlook is favorable given robust profitability and growth in electronics end-markets, but risks include elevated valuation multiples and rising debt levels. The stock offers upside potential aligned with Wall Street optimism, though investors should weigh margin pressures and capital expenditure trends.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
